- Q4 2023 Vaxcyte Inc Earnings Call TranscriptFeb 27, 2024$81.05 (+2.63%)Earnings
- Vaxcyte Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Vaxcyte Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Vaxcyte Inc VAX-24 Phase 2 65+ Adult Study Results Call TranscriptApr 17, 2023
- Q4 2022 Vaxcyte Inc Earnings Call TranscriptFeb 27, 2023$42.3 (+1.44%)Earnings
- Vaxcyte Inc VAX-24 Phase 1/2 Proof-of-Concept Study Topline Data Call TranscriptOct 24, 2022
- Vaxcyte Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Vaxcyte Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Q4 2021 Vaxcyte Inc Earnings Call TranscriptFeb 28, 2022$23.17 (+2.52%)Earnings
- Vaxcyte Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) TranscriptOct 05, 2021
- Vaxcyte Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q4 2020 Vaxcyte Inc Earnings Call TranscriptMar 29, 2021Earnings
Vaxcyte Inc VAX-24 Phase 2 65+ Adult Study Results Call Transcript
Good morning. My name is Ashley, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte conference call to discuss the VAX-24 Phase II adult program, including the Phase II study results in adults aged 65 and older. (Operator Instructions) I would now like to turn the call over to Andrew Guggenhime, Chief Financial Officer of Vaxcyte. Please go ahead, sir.
Thank you, Ashley, and good morning, everyone. I'd like to welcome you to Vaxcyte conference call to discuss data from our Phase II study evaluating the safety, tolerability and immunogenicity of VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine in healthy adults aged 65 and older.
Additionally, we will be discussing full 6-month safety data from the adult Phase I/II and Phase II study as well as the prespecified pooled immunogenicity analyses of data from both adult Phase II studies.
I'm joined today by our Chief Executive Officer, Grant Pickering; and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)